Zacks Investment Research
17 Jul 2026, 19:32 UTC · 7w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
uniQure's lead gene therapy candidate for Huntington's disease, AMT-130, has driven a 124.4% stock price increase over the last 12 weeks. — The candidate is the primary value driver for the company in a market with no approved disease-modifying treatments.
+0.60uniQure's price-to-book value of 16.48X is significantly higher than both its industry average (2.59X) and the S&P 500 (3.69X). — Extreme valuation premiums increase the risk of a price correction if clinical or regulatory milestones are delayed.
-0.40uniQure's first-quarter 2026 revenue of $3.6 million missed the Zacks Consensus Estimate of $7 million. — A significant top-line miss indicates current commercial performance is lagging behind analyst expectations.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Selling, general and administrative expenses rose 84% to $20.1 million due to commercial hiring and AMT-130 launch preparations. — Increased operational spending reinforces a near-term loss profile and elevates the cash burn rate.
-0.20Which stocks this story touches
The stock has surged on positive reassessment of its lead candidate, although the analyst warns of a high valuation and mixed quarterly results.
Mentioned only as another stock to monitor in the Huntington's disease space without specific news.
Mentioned only as another stock to monitor in the Huntington's disease space without specific news.
[mutual] uniQure receives Hemgenix royalties under a collaboration with CSL Behring.
[mutual] Both companies are identified as Huntington's disease-related stocks for investors to monitor.
[mutual] Both companies are identified as Huntington's disease-related stocks for investors to monitor.
[mutual] Both companies are identified as Huntington's disease-related stocks for investors to monitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
The Motley Fool
1d ago
